Neoadjuvant therapy for resectable pancreatic cancers

作     者：Yosuke Inoue Hiromichi Ito Yu Takahashi 

作者机构：Division of Hepato-Biliary-Pancreatic SurgeryCancer Institute HospitalJapanese Foundation for Cancer ResearchTokyoJapan 

出 版 物：《Hepatobiliary Surgery and Nutrition》 (肝胆外科与营养（英文）)

年 卷 期：2022年第11卷第4期

页      面：583-585页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：cancers therapy curative 

摘      要：Pancreatic cancer(PC)is a potentially systemic disease with more diverse biology than generally considered.At present,surgical resection is the only curative therapy available for patients with PC,and its indications have long been discussed based on anatomical resectability.A recent consensus recommends neoadjuvant therapy(NAT)for anatomically borderline resectable(BR)cancers(1)as well as induction therapy for unresectable locally advanced(UR-LA)or metastatic(UR-M)cancers.